CELC Stock Summary and Trading Ideas (Celcuity | NASDAQ:CELC)

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Celcuity trades on the NASDAQ stock market under the symbol CELC.

As of March 6, 2026, CELC stock price declined to $115.00 with 776,455 million shares trading.

CELC has a beta of 0.99, meaning it tends to be less sensitive to market movements. CELC has a correlation of 0.02 to the broad based SPY ETF.

CELC has a market cap of $5.32 billion. This is considered a Mid Cap stock.

In the last 3 years, CELC traded as high as $120.32 and as low as $7.58.

The top ETF exchange traded funds that CELC belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.

CELC has outperformed the market in the last year with a price return of +1012.2% while the SPY ETF gained +16.6%. CELC has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +8.9% and +7.7%, respectively, while the SPY returned -1.7% and -1.8%, respectively.

CELC support price is $111.52 and resistance is $118.96 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CELC shares will trade within this expected range on the day.